CUNEO, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 594
EU - Europa 441
AS - Asia 197
AF - Africa 32
SA - Sud America 1
Totale 1.265
Nazione #
US - Stati Uniti d'America 593
GB - Regno Unito 130
SE - Svezia 83
IT - Italia 69
CN - Cina 64
VN - Vietnam 63
DE - Germania 46
IE - Irlanda 31
IN - India 31
SG - Singapore 22
FR - Francia 19
RU - Federazione Russa 18
TG - Togo 15
EE - Estonia 12
ZA - Sudafrica 11
CH - Svizzera 9
JP - Giappone 7
UA - Ucraina 7
BG - Bulgaria 4
CI - Costa d'Avorio 4
GR - Grecia 4
JO - Giordania 4
BE - Belgio 2
IR - Iran 2
NG - Nigeria 2
QA - Qatar 2
RS - Serbia 2
BR - Brasile 1
CA - Canada 1
ES - Italia 1
FI - Finlandia 1
HK - Hong Kong 1
HR - Croazia 1
NL - Olanda 1
PL - Polonia 1
TR - Turchia 1
Totale 1.265
Città #
Southend 122
Fairfield 76
Chandler 63
Ashburn 42
Houston 42
Seattle 40
Dong Ket 32
Woodbridge 32
Dublin 31
Cambridge 27
Wilmington 27
Ann Arbor 25
Princeton 24
Singapore 17
Lomé 15
Beijing 13
Bologna 13
Bremen 12
Nanjing 12
Padova 12
Westminster 12
New York 9
Turin 8
Saint Petersburg 7
Berlin 6
Jinan 6
Shenyang 6
Hebei 5
Medford 5
Norwalk 5
San Diego 5
Abidjan 4
Amman 4
Bern 4
Hyderabad 4
Los Angeles 4
Nanchang 4
Rome 4
Sofia 4
Tokyo 4
Athens 3
Chicago 3
Florence 3
London 3
Redwood City 3
Torino 3
Vellore 3
Zhengzhou 3
Abeokuta 2
Andover 2
Brussels 2
Bühl 2
Changsha 2
Doha 2
Falls Church 2
Guangzhou 2
Hefei 2
Lanzhou 2
Latina 2
Olalla 2
Parma 2
Svilajnac 2
Tianjin 2
Vasto 2
Abano Terme 1
Ardabil 1
Bari 1
Castellammare di Stabia 1
Central District 1
Dearborn 1
Fremont 1
Gragnano Trebbiense 1
Groningen 1
Haikou 1
Istanbul 1
Jiaxing 1
Johannesburg 1
Lappeenranta 1
Leawood 1
Madrid 1
Maria 1
Milan 1
Monmouth Junction 1
Mountain View 1
Ningbo 1
North Bergen 1
Poggio Renatico 1
Redmond 1
San Francisco 1
Santiago 1
Taizhou 1
Winfield 1
Winnipeg 1
Zurich 1
Totale 873
Nome #
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 154
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 135
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 131
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 123
The emerging role of GSK-3β in the pathobiology of classical Hodgkin lymphoma 98
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 91
HIGH RATE OF COMPLETE HEMATOLOGICAL RESPONSE IN ELDERLY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY INNOVATIVE SEQUENTIAL USE OF NILOTINIB AND IMATINIB: A GIMEMA CLINICAL TRIAL LAL 1408 90
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia 89
Extremely high rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of Nilotinib and Imatinib. A GIMEMA Protocol LAL 1408 87
Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience 79
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia 77
Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients. 75
Isolamento e caratterizzazione immunofenotipica di cellule non-emopoietiche presenti in versamenti ascitici e pleurici di pazienti con malattie ematologiche 10
Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia 8
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 8
Cytogenetic and molecular cytogenetic profile of bone marrow-derived mesenchymal stromal cells in chronic and acute lymphoproliferative disorders 6
CXCR4 pos circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral blood of patients affected by systemic sclerosis 6
Aberrant expression of HLA-DR antigen by bone marrow-derived mesenchymal stromal cells from patients affected by acute lymphoproliferative disorders 6
Cellule staminali circolanti in pazienti con infarto miocardico 6
Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation 6
Alpha interferon in T helper phenotype chronic lymphocytic leukemia: a report of three cases 6
Cellule staminali circolanti in pazienti con infarto miocardico 6
Cytogenetic aspects of B- cell chronic lymphocytic leukemia: their correlation with clinical stage and different polyclonal mitogens 5
Total loss of p53 DNA sequences in acute myeloid leukemia 2
Studio dei progenitori emopoietici circolanti in pazienti con infarto del miocardio 2
Studio dei progenitori emopoietici e delle cellule endoteliali in cors di patologie autoimmuni: ruolo della citometria a flusso multicolore 1
Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDS-related AML 1
Totale 1.308
Categoria #
all - tutte 3.961
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.961


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020265 0 15 1 13 36 29 42 40 35 16 19 19
2020/2021176 29 11 3 2 2 6 1 7 20 6 9 80
2021/2022232 12 15 12 24 21 13 4 15 12 16 50 38
2022/2023306 21 36 14 40 17 22 7 28 57 38 18 8
2023/202496 1 21 14 12 13 13 7 2 5 5 2 1
2024/202531 19 12 0 0 0 0 0 0 0 0 0 0
Totale 1.308